Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 23;151:106623. doi: 10.1016/j.ypmed.2021.106623

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — percentage of additional cancer cases over 2020–2030 in each age group*, by setting and extent of disruption (12-month scenarios).

* Age = age in 2020, not necessarily at the time of cancer diagnosis.

Results for the US represent the midpoint of results for the two included models (Harvard and Policy1-Cervix). Model-specific US results are included in an Appendix (Fig. A4). All Norway models reflect the recommendation that women aged 25–33y be screened with 3y cytology; all US models reflect the recommendation that women aged 21–29y be screened with 3y cytology.

Fig. 2 — percentage of additional cancer cases over 2020–2030 in each age group*, by setting and extent of disruption (12-month scenarios).

* Age = age in 2020, not necessarily at the time of cancer diagnosis.

Results for the US represent the midpoint of results for the two included models (Harvard and Policy1-Cervix). Model-specific US results are included in an Appendix (Fig. A4). All Norway models reflect the recommendation that women aged 25–33y be screened with 3y cytology; all US models reflect the recommendation that women aged 21–29y be screened with 3y cytology.